CervoMed to Present Phase 2b Trial Results

The latest announcement is out from CervoMed ( (CRVO) ).

CervoMed Inc., a clinical-stage company developing treatments for neurologic disorders, will present detailed safety and efficacy results from its RewinD-LB Phase 2b trial at the International Lewy Body Dementia Conference in Amsterdam. The trial focuses on neflamapimod, a potential therapy for dementia with Lewy bodies, with topline results expected in December 2024. This development is highly anticipated given the current lack of approved therapies for this condition, drawing significant interest from the scientific community.

For an in-depth examination of CRVO stock, go to TipRanks’ Stock Analysis page.